Athenex

170 articles with Athenex

• Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Launch of a Generic Version of Magnesium Sulfate in Water for Injection, in Non-PVC, Single-Patient Use Containers by Their Partner Athenex Pharmaceutical Division (APD)

  3/20/2023

  Milla Pharmaceuticals Inc., a subsidiary of the Alter Pharma Group, announced that its partner, Athenex Pharmaceutical Division, has just started to commercialize its abbreviated new drug application approval from the U.S. Food and Drug Administration for its Generic Version of Magnesium Sulfate in Water for Injection, 2 g/50 mL, 4 g/100 mL and 4 g/50 mL, in Non-PVC, Single-Patient Use Containers.

• Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update

  3/20/2023

  Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today provided a corporate and financial update for the fourth quarter and full year ended December 31, 2022.

• Athenex Announces a Reverse Stock Split - February 14, 2023

  2/14/2023

  Athenex, Inc. announced that it will effect a 1-for-20 reverse stock split of its issued common stock, effective at 12:01 a.m. Eastern Time on February 15, 2023.

• Athenex Announces MHRA Decision on Oral Paclitaxel

  1/3/2023

  Athenex, Inc. announced that its proprietary Oral Paclitaxel formulation did not receive regulatory approval from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency for metastatic breast cancer based solely on CMC issues.

• Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel

  12/20/2022

  Athenex, Inc. announced that collaborators at the Quantum Leap Healthcare Collaborative reported today that the Company’s oral paclitaxel plus encequidar in combination with a PD-1 inhibitor and carboplatin has graduated in the triple-negative subgroup of high-risk early-stage breast cancer.

• Athenex Announces Positive Results of Special Stockholder Meeting

  11/22/2022

  Athenex, Inc. announced the results of its special meeting of stockholders, held as a virtual meeting on November 22, 2022.

• Athenex Announces Closing of the Sale of its China API Business

  11/21/2022

  Athenex, Inc. today announced the closing of the sale of its equity interests in its China subsidiaries, which primarily represent the Company’s ownership of its active pharmaceutical ingredient (API) manufacturing business in China, to Chongqing Comfort Pharmaceutical Inc. (Chongqing Comfort).

• Athenex to Participate in the 5th Annual Evercore ISI HealthCONx Conference

  11/8/2022

  Athenex announced that management will participate in the 5th Annual Evercore ISI HealthCONx Conference, taking place virtually November 29 to December 1, 2022.

• Athenex Provides Third Quarter 2022 Financial Results and Business Update

  11/3/2022

  Athenex, Inc. provided a corporate and financial update for the third quarter ended September 30, 2022.

• Athenex Announces Receipt of Positive Nasdaq Listing Determination

  11/3/2022

  Athenex, Inc. announced that a Nasdaq Hearings Panel has granted the company's request for continued listing on The Nasdaq Stock Market, subject to the Company’s satisfaction of the minimum $1.00 bid price requirement by March 14, 2023.

• Athenex to Provide Corporate and Financial Update for the Third Quarter 2022 on November 3, 2022

  10/24/2022

  Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the third quarter 2022 on Thursday, November 3, 2022, before the market opens.

• Athenex Files Definitive Proxy Statement for Special Stockholder Meeting

  10/11/2022

  Athenex, Inc. announced that it has filed a definitive proxy statement with the Securities and Exchange Commission in connection with a special meeting of stockholders scheduled on November 22, 2022.

• Athenex, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants

  8/11/2022

  Athenex intends to use the net proceeds from the proposed offering to fund ongoing clinical development for its product candidates and for working capital and other general corporate purposes.

• Athenex, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants - Aug 10, 2022

  8/10/2022

  Athenex, Inc. announced that it intends to offer and sell, subject to market conditions, shares of its common stock, or pre-funded warrants to purchase common stock in lieu of common stock to certain investors, and accompanying warrants to purchase shares of its common stock, in an underwritten public offering.

• Athenex Provides Second Quarter 2022 Financial Results and Business Update

  7/28/2022

  Athenex, Inc. today provided a corporate and financial update for the second quarter ended June 30, 2022.

• Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clinical Oncology

  7/25/2022

  Athenex, Inc., (NASDAQ: ATNX), today announced the publication of their manuscript, “Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer”.

• Athenex to Provide Corporate and Financial Update for the Second Quarter 2022 on July 28, 2022

  7/21/2022

  Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the second quarter 2022 on Thursday, July 28, 2022, before the market opens.

• Athenex Announces Entry into Agreement to Sell its China API Business to TiHe Capital (Bejing) Co., Ltd.

  7/11/2022

  Athenex, Inc. announced that Athenex and certain affiliates have entered into an agreement to sell all of its equity interests in its China subsidiaries, which are primarily engaged in Active Pharmaceutical Ingredient manufacturing operations, to TiHe Capital Co., Ltd. for RMB 124.4 million, or approximately $19.0 million.

• Athenex to Participate in Truist Securities Cell Therapy Symposium

  6/23/2022

  Athenex announced that Daniel Lang, M.D., President, Athenex Cell Therapy, will participate in The Next Cells & Mechanisms to Watch in Oncology panel at the Truist Securities Cell Therapy Symposium on Tuesday, June 28, 2022 at 11:30 am Eastern Time in New York, NY.

• Athenex Announces Sale of Revenues from U.S. and European Royalty and Milestone Interests in Klisyri® (tirbanibulin) to Sagard Healthcare Partners and Oaktree

  6/22/2022

  Athenex, Inc., (NASDAQ: ATNX), today announced the signing of a definitive agreement for the sale of revenues from U.S. and European royalty and milestone interests in Klisyri® (tirbanibulin) to Sagard Healthcare Partners and funds managed by Oaktree Capital Management, L.P. (“Oaktree”) for $85 million.